We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Occurence of Inflammation and Oxidative Stress in Lung Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00512967
Recruitment Status : Completed
First Posted : August 8, 2007
Last Update Posted : February 24, 2017
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center

Brief Summary:

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.

The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD

Condition or disease
Interstitial Lung Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis COPD

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 76 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants
Study Start Date : September 2005
Study Completion Date : June 2006

21 onset patients, non-treated
15 IPF patients, partially treated
15 COPD patients within 24 hours after their last exacerbation
25 healthy controls, matched for age and gender

Biospecimen Retention:   Samples With DNA
blood samples were collected

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
lung patients visiting the out-patient clinic of the Academic Hospital Maastricht

Inclusion Criteria:

  • clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
  • no treatment for sarcoidosis
  • last exacerbation not more than 24 hours ago for COPD
  • healthy controls
  • no smoking for sarcoidosis and IPF

Exclusion Criteria:

  • pregnancy
  • use of vitamins or food supplements
  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00512967

Maastricht University
Maastricht, Netherlands, 6224 LH
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Study Chair: Aalt Bast, PhD Maastricht University
Principal Investigator: Agnes W Boots, PhD Maastricht University
Study Director: Guido R Haenen, PhD Maastricht University

Responsible Party: Dr. A.W. Boots, Maastricht University
ClinicalTrials.gov Identifier: NCT00512967     History of Changes
Other Study ID Numbers: MEC 03-112
First Posted: August 8, 2007    Key Record Dates
Last Update Posted: February 24, 2017
Last Verified: February 2008

Keywords provided by Maastricht University Medical Center:
oxidative stress

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs